Answers are grounded in this paper and cite their sources.
Purpose Herpes simplex virus-1 (HSV-1) keratitis is a leading cause of infectious corneal blindness. Current treatment primarily relies on antiviral agents such as acyclovir (ACV) that inhibit active viral replication but do not eradicate latent HSV-1 and completely prevent recurrence. Antimicrobial peptides (AMPs) have emerged as promising alternatives because of their antimicrobial properties. KR-12 has demonstrated antibacterial activity. Evaluating KR-12 antiviral efficacy may provide new therapeutic opportunities for HSK.Methodology Human corneal epithelial cells were cultured and infected with the HSV-1 KOS strain. Viral stocks were propagated and quantified by plaque assay. Cytotoxicity was assessed using the MTT assay, while antiviral efficacy was evaluated through plaque reduction assay, RT-qPCR, and immunofluorescence staining. Combination experiments with ACV were performed to assess additive antiviral effects.Results KR-12 exhibited minimal cytotoxicity at 100 µg mL−1, the selected working concentration. However, pre-treatment with KR-12 demonstrated no antiviral efficacy. At lower multiplicities of infection (MOIs), ACV consistently reduced plaque formation, whereas KR-12 remained ineffective. Combination treatment achieved 96.9% inhibition, primarily attributable to ACV. KR-12 alone demonstrated 17.5% inhibition, with no additive benefit observed.Conclusion KR-12 did not show antiviral efficacy against HSV-1. Future strategies involving peptide stabilization and chemical modification may improve its antiviral potential and translational applicability.
No takes yet. Share an insight, caveat, or question.
Gagan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: